Navigation Links
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Date:8/15/2013

fficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves.

Use of PRADAXA for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.

Effect of P-gp Inducers & Inhibitors on Dabigatran Exposure 
The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS 
In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in higher rates of major GI bleeds and any GI bleeds compared
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
11. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and CEO ... reduce prescription fraud and abuse in Medicare Part D ... Fighting Back on Many Fronts ," sponsored by the ... The briefing featured several government and industry experts discussing ... Centers for Disease Control and Prevention has labeled the ...
(Date:9/29/2014)... CITY , Sept. 29, 2014 ... scheduled a conference call for investors today at ... the quarter and year ended June 30, 2014.  ... participating is (800) 771-7941. Dynatronics manufactures, ... goods and supplies, treatment tables and rehabilitation equipment ...
(Date:9/29/2014)... 2014 EU5 Esophagoscopes & Gastroscopes Market ... report, "EU5 Esophagoscopes & Gastroscopes Market Outlook to ... Esophagoscopes & Gastroscopes market. The report provides value, ... and average prices (in US dollars) within market ... Gastroscopes and Flexible Video Gastroscopes. ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:9/30/2014)... Pyramid Analytics, worldwide leader in Governed ... of Veterans Affairs has selected Pyramid Analytics ... Business Intelligence platform. This partnership will enable the ... enabling more than 30,000 users with insights that ... and reporting capabilities. , The strategic selection comes ...
(Date:9/30/2014)... “Biology and botany are having ... “and it’s about naming rights.” , In ... on the Bryan William Brickner Blog, the focus ... of Health (PubMed). The post highlights five cannabinoid ... transitions, aging with THC, the wake-inducing effects of ...
(Date:9/30/2014)... September 30, 2014 A trailblazer at heart, ... seeks out upcoming medical breakthroughs in spine repairs. His ... seen in his patients in which he has implanted the ... its components are state-of-the art and mimic normal human disc ... has also been proven to be an exceptional replacement device ...
(Date:9/30/2014)... 30, 2014 3M has added four new ... bond tapes. 3M 5906 , 3M 5907 , ... conformable VHBs which help create the strongest bond possible to ... used for bonding to difficult surfaces such as paints, low ... 5907, 5908, and 5905 are designed specifically for electronic device ...
(Date:9/30/2014)... Dogs are social animals, and love to go everywhere with ... travelling from place to place. Many dog owners choose to ... this is not only unsafe for the dog, but unsafe ... shares with readers why keeping a dog restrained in a ... ways a dog can become injured by riding freely in ...
Breaking Medicine News(10 mins):Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... June 7th, Little Hearts, Inc. held their 13th annual celebration ... services they offer is their "Picture of Hope" -- a ... from infant to 50 of all different types of heart ... and Tricuspid Atresia. "HOPE" is shared with others on ...
... two hours of slumber a night, study suggests , MONDAY, ... computer games can be a nocturnal nightmare for some people, ... sleep at night, then spend their days struggling to stay ... between the two, the study found. , The study revealed ...
... 8 Taste and nutrition have long been topics ... so much uncertainty about what products are healthy in ... way by delivering delicious, convenient and nutritious foods to ... the release of Sunsweet Antioxidant Blend, a delicious combination ...
... the Shelves for Father,s Day , , NEW YORK, June ... back pain may lie in a $59.99 biomechanically-engineered foam and rubber ... point for the sixty million adults who reported persistent back pain ... to be a medical breakthrough is now available in the Dass, ...
... -- Eating disorders are a chronic mental health ... 1 million males in the United States. Through access ... organizations (IROs) provide a simple and lasting solution to ... and laxative abuse. Additionally they deliver the appropriate standard ...
... Cedars-Sinai Outpatient Cancer Center Appointed COO , , ... today announced the appointment of Paul R. O,Dea to ... formerly Vice President, Aptium Oncology and Executive Director, Cedars-Sinai ... hospital-based cancer centers. The appointment was effective June 1, ...
Cached Medicine News:Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2Health News:Too Much Computer Gaming Can Steal Your Sleep 2Health News:Too Much Computer Gaming Can Steal Your Sleep 3Health News:Sunsweet Introduces New Antioxidant Blend, a Delicious Blend of High Antioxidant Fruits 2Health News:Sunsweet Introduces New Antioxidant Blend, a Delicious Blend of High Antioxidant Fruits 3Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:Health Plans and IROs Can Work Together to Determine Proper Care for Eating Disorders 2Health News:Aptium Oncology Names New Chief Operating Officer 2
... Elite II features a diagnostic ... of Glasgow,(UG) algorithm. Unlike competitive ... age, the UG,algorithm bases its ... gender, age, race, medication,and classification., ...
... test face is a LogMAR ... Landolt C in various orientations ... targets are presented at 10% ... useful for evaluating the low ...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: